

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣葯業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1681)**

## **VOLUNTARY ANNOUNCEMENT**

### **DRUG REGISTRATION APPROVALS OF THE GROUP'S "IOPAMIDOL INJECTION"**

This announcement is made by Consun Pharmaceutical Group Limited (the **"Company"**, together with its subsidiaries, the **"Group"**) on a voluntary basis to provide its shareholders and potential investors with the information of the latest business development of the Group.

The board (the **"Board"**) of directors (the **"Directors"**) of the Company is pleased to announce that, the respective drug registration approvals of the "Iopamidol Injection" (the **"Product"**) of two specifications, namely 100ml:30g(I) and 100ml:37g(I), developed by Guangzhou Consun Pharmaceutical Company Limited, an indirect wholly-owned subsidiary of the Group, have been granted by the National Medical Products Administration of the People's Republic of China (the **"PRC"**).

The Product is a contrast medium for computer tomography and is applicable to the imaging of lesions in all body parts. The iodine concentration of the Product of the specification of 100ml:37g(I), which is the highest iodine concentration for application within the PRC and is particularly applicable to angiography, possesses comparative technical edge. In addition, as a non-ionic iodinated contrast medium, when compared with other ionic iodinated contrast medium, the Product can improve the quality of imaging, the scope of vascular imaging, the clearness of images from computer tomography and the diagnostic accuracy of digital vascular subtraction. With its outstanding product features, the Product is expected to have good market prospects.

The acquisition of approvals of the Product will further enrich the Group's product portfolio of contrast medium, thus facilitating its development in the medical contrast medium field.

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Yubao**  
*Chairman*

Hong Kong, 15 July 2019

*As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.*